Boston, MA -- (ReleaseWire) -- 04/16/2014 -- The Brazilian pharmaceutical market remains the most attractive to multinational pharmaceutical companies in Latin America. The expansion of healthcare coverage, driven by local authorities, presents significant revenue-generating opportunities for drugmakers and healthcare service providers. However, given the Brazilian government's protectionist measures in the pharmaceutical sector, we believe local drugmakers will outpace multinationals.
Headline Expenditure Projections
- Pharmaceuticals: BRL57.0bn (US$26.4bn) in 2013 to BRL61.6bn (US$26.2bn) in 2014; +8.2% in local currency terms and -0.7% in US dollars terms. Forecast revised upwards from Q114 due to changes to macroeconomic forecast.
- Healthcare: BRL438.6bn (US$203.2bn) in 2013 to BRL484.9bn (US$206.3bn) in 2014; +10.6% in local currency terms and 1.5% in US dollars. Forecast revised upwards from Q114 due to more optimistic macroeconomic forecast data.
View Full Report Details and Table of Contents
Risk/Reward Rating: Brazil scores 60.3 in BMI's Pharmaceutical and Healthcare Risk/Reward Rating (RRR) matrix, making it the fifth-most attractive pharmaceutical market in America. We note that the weakening real against the US dollar was the key factor that has caused Brazil's to fall behind Mexico this quarter, as we assess market data in US dollar terms to allow cross country comparison in the RRR calculation.
Key Trends And Developments
- In February 2014, Brazil's Ministry of Health released a proposal recommending new clinical protocols to treat children with HIV.
- In February 2014 Brazil's Health Minister Alexandre Padilha signed a decree to incorporate 15 new tests for rare disease diagnosis in the Unified Health System (SUS).
- In January 2014, Brazil's National Economic Development Bank (BNDES) planned to invest up to BRL10bn (US$4.1bn) in the production of biopharmaceutical products by 2016.
- In January 2014, the Pharmaceutical Products Industry Union in the State of Sao Paulo (Sindusfarma) expressed the industry's concerns over the delay in the publication of the Brazilian government's medicine pricing policy - the first delay in nine years.
- In December 2013, the Brazilian Commission of Social Security and Family approved a proposal to increase the federal budget for healthcare to 18.7% of total spending by 2018. The federal healthcare expenditure will rise at the following pace: 15% in 2014, 16% in 2015, 17% in 2016, 18% in 2017, and 18.7% in 2018.
In November 2013, Brazil's National Health Surveillance Agency (ANVISA) published new regulation, Resolucao da Diretoria Colegiada (RDC) 38/2013, to enable patient access to new drugs before they are officially approved and available for purchase.
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Healthcare research reports at Fast Market Research
You may also be interested in these related reports:
- Sweden Pharmaceuticals & Healthcare Report Q2 2014
- Kenya Pharmaceuticals & Healthcare Report Q2 2014
- Croatia Pharmaceuticals & Healthcare Report Q2 2014
- Bangladesh Pharmaceuticals & Healthcare Report Q2 2014
- Mexico Pharmaceuticals & Healthcare Report Q2 2014
- Bulgaria Pharmaceuticals & Healthcare Report Q2 2014
- Thailand Pharmaceuticals & Healthcare Report Q2 2014
- Kazakhstan Pharmaceuticals & Healthcare Report Q2 2014
- Lebanon Pharmaceuticals & Healthcare Report Q2 2014
- Japan Pharmaceuticals & Healthcare Report Q2 2014